Table 3 Univariate and multivariable analysis of survival
Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | |
Demographics | ||||
Sex (female = 1) | 1.27 (0.56–2.92) | .569 | ||
Age (≤ 60 years = 1) | 2.18 (0.96–4.93) | .063 | excluded | |
BMI (≤ 25 kg/m2 = 1) | 1.30 (0.16–10.33) | .803 | ||
ASA (I/II = 1) | 1.47 (0.61–3.56) | .393 | ||
Oncological data | ||||
Timing (synchronous = 1) | 2.03 (0.90–4.58) | .090 | excluded | |
Site of primary | .471 | |||
Right-sided colon | 1 | |||
Left-sided colon | 0.50 (0.17–1.48) | |||
Rectum | 0.67 (0.22–2.03) | |||
T category primary (T1/T2 = 1) | 4.80 (0.63–36.67) | .131 | ||
N category primary (N0 = 1) | 0.60 (0.22–1.67) | .330 | ||
Preoperative chemotherapy (no = 1) | 1.92 (0.57–6.46) | .292 | ||
Second-line treatment (no = 1) | 1.03 (0.38–2.76) | .958 | ||
Number of cycles of chemotherapy | .060 | .024 | ||
≤ 6 | 1 | 1 | ||
> 6 | 3.38 (0.95–12.03) | 5.92 (1.26–27.78) | ||
Antibody utilization (no = 1) | 1.29 (0.57–2.90) | .540 | ||
Response to chemotherapy | .024 | .013 | ||
Stable disease | 1 | 1 | ||
Partial remission | 0.32 (0.13–0.78) | 0.17 (0.05–0.55) | ||
Progressive disease | n. a. | n. a. | ||
Number of lesions at hepatectomy | .763 | |||
≤ 3 | 1 | |||
> 3 | 1.14 (0.48–2.70) | |||
Largest tumor diameter at hepatectomy | .099 | excluded | ||
≤ 35 | 1 | |||
> 35 | 1.98 (0.88–4.44) | |||
Clinical chemistry | ||||
AST (≤ 30 U/l = 1) | 0.52 (0.23–1.17) | .112 | ||
ALT (≤ 30 U/l = 1) | 0.78 (0.35–1.75) | .550 | ||
GGT (≤ 75 U/l = 1) | 1.00 (0.44–2.27) | .944 | ||
Bilirubin (≤ 0.4 mg/dl = 1) | 1.54 (0.68–3.48) | .296 | ||
Alkaline phosphatase (≤ 105 U/l = 1) | 1.87 (0.81–4.30) | .143 | ||
INR (≤ 1 = 1) | 0.77 (0.32–1.85) | .553 | ||
Prothrombin time (≥ 100% = 1) | 0.86 (0.37–2.02) | .731 | ||
Hemoglobin (≤ 13 g/dl = 1) | 0.77 (0.34–1.73) | .520 | ||
CRP, mg/l (≤ 10 mg/l = 1) | 2.38 (1.02–5.57) | .045 | excluded | |
Operative and inter-stage data | ||||
Operative approach | .954 | |||
ALPPS | 1 | |||
TSH | .976 (0.43–2.23) | |||
Operative time step 1 (≤ 180 min = 1) | 1.02 (0.42–2.45) | .972 | ||
Blood transfusion step 1 (no = 1) | 1.18 (0.47–2.98) | .772 | ||
Interval between stages (≤ 35 days = 1) | 0.69 (0.28–1.67) | .408 | ||
Inter-stage chemotherapy (no = 1) | 0.04 (0.01–4.11) | .171 | ||
Completion (no = 1) | 0.46 (0.06–3.67) | .460 | ||
Operative time step 2 (≤ 240 min = 1) | 0.83 (0.37–1.86) | .649 | ||
Blood transfusion step 2 (no = 1) | 1.66 (0.73–3.78) | .231 | ||
Pathological data | ||||
R1 resection (no = 1) | 0.04 (0.01–44.68) | 475 | ||